Search the Newsreel

Aquestive Therapeutics president and CEO Daniel Barber sells $100,191 in stock

Aquestive Therapeutics President and CEO Daniel Barber sold a total of $100,191 worth of company stock through two transactions on July 15 and July 16, 2026. These sales reduced his direct ownership to 610,574 shares. The sales occurred while the stock was trading at …

Frequency Electronics (NASDAQ:FEIM) Trading 8.5% Higher - Time to Buy?

Enterprise value to EBITDA forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST

This page provides information on the enterprise value to EBITDA forward for Aquestive Therapeutics, Inc. (NASDAQ:AQST). It is part of a larger financial data and market analysis platform, offering various tools and community features for investors. The content specifically highlights the financial metric for …

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 1.43% on Monday, closing at $207.66. This underperformance occurred on a generally negative trading day, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a two-day winning streak.

Quest Diagnostics Q2 2026 Earnings Preview — July 23, Street Expects $2.82 EPS

Quest Diagnostics is set to announce its second-quarter earnings on July 23, with analysts expecting $2.82 EPS on revenue of $2.97 billion, representing significant year-over-year growth. Despite a 100% beat rate in its last quarter, analyst EPS estimates have seen a modest downward revision …

Quest Diagnostics stock trades steady as investors weigh recent earnings and volume trends

Quest Diagnostics stock is trading steadily as investors assess its recent earnings and volume trends, driven by diagnostic testing demand and margin performance. The company's financial health is supported by resilient testing volumes, cost-management initiatives, strong cash flow, and strategic investments in technology and …

Quest Diagnostics (DGX) Expands Oncology Test Access, Is The Stock Fully Valued?

Quest Diagnostics (DGX) has expanded access to its oncology tests by integrating them into Flatiron Health’s OncoEMR platform, a move boosting investor interest. Despite recent strong stock performance, Simply Wall St assesses DGX as 5.7% undervalued with a fair value of $223.44, driven by …

Quest Diagnostics | SCHEDULE 13G/A: Others

This article is a financial filing document, specifically a SCHEDULE 13G/A, related to Quest Diagnostics. The "Others" designation suggests a filing by a category of investor other than an institutional manager, perhaps an individual or a passive investor group revealing beneficial ownership.

Behavioral Patterns of HQI and Institutional Flows

This article analyzes behavioral patterns for Hirequest, Inc. (NYSE: HQI), identifying strong near-term sentiment that could shift to neutral mid-term and positive long-term biases. It details specific AI-generated trading strategies with entry/target/stop-loss points for position, momentum, and risk-hedging, alongside multi-timeframe signal analysis for support …

Frequency Electronics Inc (FEIM) Q4 2026 Earnings Call Highlights: Navigating Challenges and ...

Frequency Electronics Inc (FEIM) reported a Q4 2026 revenue of $15.4 million, down from the prior year, but achieved a record funded backlog of $111 million, indicating strong future revenue potential. The company is strategically expanding into high-growth markets like space defense and quantum …

DGX4986719 Bond Risk Profile

This article provides a risk profile for the Quest Diagnostics Incorporated 2.8% bond, identified as DGX4986719. It highlights key metrics for assessing credit risk, such as security level, inflation protection, and issuer rating. The profile aims to help investors evaluate the bond's reliability and …

Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04

Aquestive Therapeutics (AQST) CEO Daniel Barber sold a total of 25,000 common shares on July 15-16, 2026, at prices ranging from $4.00 to $4.04 per share. These transactions were executed under a Rule 10b5-1 trading plan. Following the sales, Barber directly holds 610,574 shares …

Quest Diagnostics stock holds near results driven levels

Quest Diagnostics stock performance is being evaluated based on its recent earnings metrics, including quarterly revenue of $2.62 billion, adjusted diluted EPS of $2.64, and an adjusted operating margin of 15.0%. The company's core diagnostic testing franchise is its primary earnings driver, with testing …

Frequency Electronics (FEIM) sets up $100M shelf and 1M-share resale

Frequency Electronics, Inc. (FEIM) has filed a mixed shelf offering registration (S-3) for up to $100 million in common stock, preferred stock, and/or warrants. Additionally, selling stockholders may resell up to 1 million shares of existing common stock. The company plans to use any …

Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE

Aquestive Therapeutics Inc (AQST) President and CEO Daniel Barber sold 25,000 shares of the company on July 16, 2026, reducing his total holdings to 610,574 shares. This transaction follows a pattern of 19 insider sells and no buys over the past year. With the …

Digi Power X (DGX) Registration filing Summary

Digi Power X (DGX) has filed a registration summary outlining its business model, financial performance, and use of proceeds. The company develops and operates advanced data centers for sustainable energy, high-performance computing, Bitcoin mining, and AI/GPU infrastructure. DGX recently closed a $6.6 million private …

Form 4 Aquestive Therapeutics Inc For: 17 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Aquestive Therapeutics Inc., dated July 17. It simply announces the availability of this standard insider transaction report for the public record.

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged corporate wrongdoing. The law firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The …

Frequency Electronics (NASDAQ: FEIM) swings to loss, backlog climbs to $111M

Frequency Electronics (

FREQUENCY ELECTRONICS INC FY 2026: Revenue $63.23M, EPS ($0.09) — 10-K Summary

FREQUENCY ELECTRONICS INC (FEIM) reported fiscal year 2026 revenue of $63.23M and a net loss of ($903K), resulting in a diluted EPS of ($0.09). This marks a significant decline compared to the previous year's revenue of $69.81M and net income of $23.69M (diluted EPS …

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics (DGX) has integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Health’s OncoEMR, making it easier for oncology clinicians to access these advanced diagnostic tests. This move supports Quest's strategy to expand high-value, data-driven testing, …

ETFs Investing in Quest Diagnostics Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Quest Diagnostics Incorporated (DGX) stocks. It provides a detailed table including each fund's market value, weight

Enterprise value to EBIT forward of Quetta Acquisition Corporation – NASDAQ:QETAU

This article provides a financial snippet for Quetta Acquisition Corporation (NASDAQ: QETAU), focusing on its Enterprise Value to EBIT forward metric. The content highlights the stock's market status as closed with no trades and lists basic overview information and navigation to other financial data. …

Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends

Quest Diagnostics stock reflects a balance between stable revenue growth and margin pressures. Recent financial results show the company managing the transition from pandemic-related testing to routine services, maintaining mid-single-digit revenue growth and mid-teens operating margins, despite a slight decline in net income. The …

Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Report - Results, Call & Slides

Aquestive Therapeutics, Inc. (AQST) reported its Q3 2025 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$0.14 against a consensus of -$0.13, and actual revenue of $12.81M compared to an expected $12.97M. The report includes details on past …

Frequency Electronics Reports Weak Q4 2026 as EPS Misses by 46.7%

Frequency Electronics (NASDAQ:FEIM) reported a weak Q4 2026, with diluted loss per share of -$0.50, significantly missing the $0.27 estimate and a 46.7% miss against an earlier $0.30 estimate. Revenue declined by 23.0% to $15.4M due to headwinds in the communication equipment sector, leading …

DGX.GL Bond Profile — Key Metrics

This article provides key metrics for the DGX.GL bond, issued by Quest Diagnostics, Inc. The bond has a 5.75% coupon rate and matures on January 30, 2040, with an outstanding amount of $249.24 million. Quest Diagnostics, Inc. is a diagnostic testing and information services …

Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST

This article provides financial information for Aquestive Therapeutics, Inc. (NASDAQ:AQST), specifically focusing on its enterprise value to EBIT forward. It indicates that the company's financial data and SEC filings are available through TradingView, supported by various financial data providers.

Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth

Quest Diagnostics stock reflects the company's significant position as a major US clinical laboratory operator, benefiting from a steady, long-term demand for diagnostic services. The company's large-scale network, operational efficiency, and role in chronic disease management and public health are key pillars of its …

Why Frequency Electronics Stock Is Plummeting Today

Frequency Electronics (FEIM) Q4 2026 earnings summary

Frequency Electronics (FEIM) reported its Q4 and full-year 2026 earnings, detailing a transitional year with revenue digestion but setting the stage for significant growth. The company achieved a record funded backlog of $111 million and secured major contracts in high-growth markets like space defense …

Form 144 Aquestive Therapeutics For: 15 July By Investing.com

This article from Investing.com announces a Form 144 filing for Aquestive Therapeutics on July 15. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates of Aquestive Therapeutics plan to sell shares. The brief piece provides limited …

Press Release: Frequency Electronics, Inc. Announces Fourth Quarter and Fiscal Year 2026 Financial Results

Frequency Electronics, Inc. has announced its financial results for the fourth quarter and the full fiscal year ended April 30, 2026. The company reported a significant increase in net sales for the quarter compared to the prior year, driven by higher government sales. Despite …

Frequency Electronics Sets 50% Gross-Margin Target by 2029

Frequency Electronics (NASDAQ: FEIM) announced fiscal year 2026 results, reporting a revenue decline to $63.2 million and an operating loss of $3.0 million, yet achieved a record funded backlog of $111 million. The company reaffirmed its 2029 revenue target of $150 million and set …

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 2.05% on Wednesday, closing at $201.77. This underperformance occurred despite a favorable trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marked the ninth consecutive …

EnQuest Moves Closer to Completing Major Malaysian Acquisition (ENQ)